Hardy Reed LLC Takes $1.14 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Hardy Reed LLC purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 11,660 shares of the medical equipment provider's stock, valued at approximately $1,138,000.

Several other institutional investors also recently added to or reduced their stakes in LNTH. Verdence Capital Advisors LLC raised its stake in shares of Lantheus by 44.8% during the first quarter. Verdence Capital Advisors LLC now owns 4,800 shares of the medical equipment provider's stock worth $468,000 after acquiring an additional 1,484 shares in the last quarter. Segall Bryant & Hamill LLC bought a new stake in shares of Lantheus during the 1st quarter valued at $5,558,000. Victory Capital Management Inc. boosted its holdings in shares of Lantheus by 41.2% during the 1st quarter. Victory Capital Management Inc. now owns 123,067 shares of the medical equipment provider's stock valued at $12,011,000 after buying an additional 35,937 shares in the last quarter. Signaturefd LLC boosted its holdings in shares of Lantheus by 36.5% during the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 116 shares in the last quarter. Finally, Hughes Financial Services LLC bought a new position in Lantheus in the 1st quarter worth about $81,000. Institutional investors own 99.06% of the company's stock.

Lantheus Trading Down 4.6%

LNTH stock traded down $3.42 during trading on Friday, reaching $70.18. 1,351,740 shares of the stock traded hands, compared to its average volume of 980,999. The business's 50 day moving average price is $78.80 and its 200-day moving average price is $89.44. Lantheus Holdings, Inc. has a 52-week low of $69.12 and a 52-week high of $118.71. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46. The firm has a market capitalization of $4.86 billion, a PE ratio of 19.94 and a beta of 0.12.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The business had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. During the same period last year, the company earned $1.69 earnings per share. The business's quarterly revenue was up .8% compared to the same quarter last year. As a group, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Truist Financial reduced their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. B. Riley cut their price objective on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday, June 23rd. William Blair reaffirmed a "market perform" rating on shares of Lantheus in a report on Wednesday. Finally, Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $131.20.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director owned 318,650 shares in the company, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.50% of the stock is owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.